神经丝轻链蛋白在周围神经病中的应用价值探究

Value of Neurofilament Light Chain as a Biomarker in Peripheral Neuropathy

神经丝轻链蛋白(NfL)已被确定为许多中枢神经系统疾病中轴突损伤的生物标志物,近年来关于NfL在周围神经病中的应用价值也逐渐引起关注。本研究回顾了血清NfL(sNfL)与各种免疫介导的周围神经病〔吉兰巴雷综合征(GBS)、慢性炎性脱髓鞘性神经根神经病(CIDP)等〕、遗传性周围神经病、药物相关性周围神经病、糖尿病周围神经病等轴突损伤的动态变化之间的关系,综合分析的结论为:sNfL定量可作为一个非常有潜力的生物标志物,监测疾病活动,评估疾病短期预后、长期预后,还可作为未来的临床试验和监测治疗反应的指标。

Neurofilament light chain(NfL)has been identified as a biomarker of axonal injury in a variety of central nervous system diseases.The value of NfL as a biomarker in peripheral neuropathy has gained increasing attention.We reviewed the relationships of serum NfL with and the dynamics of axonal injury in various immune-mediated peripheral neuropathies(such as Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy),hereditary peripheral neuropathy,drug-induced peripheral neuropathies and diabetic peripheral neuropathy,and drew a conclusion after a comprehensive analysis:the quantified NfL may be used as a promising biomarker to monitor disease activity,assess short-and long-term prognosis,and also as a potential biomarker for clinical trials and monitoring treatment response.